Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

US False Claims Act

Genesis Research Group A&P image

Strategy. Insights. Access. Genesis Research Group outlines its integrated, data-driven solutions for US and global access and pricing.

In today’s rapidly evolving environment, US and global access and pricing decisions demand robust evidence, rigorous analysis, and strategic precision. Following Genesis Research Group's recent expansion of its real-world data...

Genesis Research Group

- PMLiVE

Communicating value to US Payers: Insights for Pharma and Medtech

What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging...

Petauri Evidence

- PMLiVE

Kathy O’Connell joins Research Partnership as Senior Vice President, Business Development

Kathy has been working in the pharmaceutical market research industry for over 25 years. She has a diverse business background, with in-depth experience in progressively responsible sales, business development and...

Inizio

- PMLiVE

US backs proposal to waive IP protection for COVID-19 vaccines

"Monumental decision" could see IP protections for COVID-19 vaccines temporarily removed

- PMLiVE

Takeda to sell Japan consumer health unit for $2.3bn

Deal helps to reduce debt accrued from Shire takeover

- PMLiVE

Mergers and acquisitions: agents for change

Getting the best from your agency in a disruptive time

Bedrock Healthcare Communications

Lighthouse Medical Communications US – An opportunity of a lifetime to be part of the Lucid Group magic

Our family at Lighthouse Medical Communications US are looking for talented individuals to join its team in hashtagManhattan. If you want to be part of something magical get in touch...

Lucid Group Communications Limited

- PMLiVE

Takeda’s subcutaneous Entyvio formulation faces FDA rejection

Was seeking approval in moderate-to-severe ulcerative colitis

- PMLiVE

Takeda highlights 12 NMEs with $10bn-plus sales potential at R&D day

First wave of new molecular entities has potential to generate 14 approvals

- PMLiVE

Takeda divests over-the-counter and prescription drugs to Stada for $660m

Japanese pharma said it has plans to divest $10bn in non-core assests

- PMLiVE

Takeda offloads select portfolio to Acino ahead of Shire takeover

Hopes to reduce debt before acquistion completion

It’s the guns, stupid

Gun violence in the US – a public health issue – can be better understood through three points

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links